Blind Spots in Fighting the Outbreak of Coronavirus Disease 2019

Lanjing Zhang*

Department of Pathology, Princeton Medical Center, Plainsboro, NJ, USA; Department of Biological Sciences, Rutgers University, Newark, NJ, USA; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA; Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA

Abstract

The recent outbreak of 2019 novel coronavirus infection has involved more than 110,000 people and 105 countries. Many efforts have been made to prevent, contain and treat the related disease (named as coronavirus disease 2019). However, many blind spots might not yet receive needed attention. I here discuss eight blind spots that may interest related parties. If these issues remain outstanding, they will likely lead to many severe harms to the public, healthcare providers and the economy. Additional research is therefore needed to better understand and address these blind spots in fighting the outbreak of coronavirus disease 2019.

Recently, the outbreak of 2019 novel coronavirus infection involved more than 113,702 people and 109 countries in the word, and has led to a public health emergency of international concern. Many efforts were rightly and timely made to fight the outbreak of 2019 novel coronavirus in China, which was recently named as Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the Coronavirus Study Group, and Coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). A group of virologists in China also proposed to name the virus as human coronavirus 2019 (HCoV-19). Despite the differences in name, we observed orchestral actions from governments, health care providers, non-profit organizations and individual citizens in China and the other part of the world. As a result, the daily incidence of infection has been decreasing since February 1, 2020 according to the official websites and a trend analysis on the epidemiology of COVID-19. On the other hand, the rising incidence in Japan, Korea and Iran is alarming. A modelling study also shows that Africa might be vulnerable to the pandemic of COVID-19. Indeed, there were 10,566 COVID-19 cases in WHO member states outside of China on March 3, 2020, which was developed within the past 2 weeks. On March 3 alone, 8 new member states of the WHO (namely Andorra, Jordan, Latvia, Morocco, Portugal, Saudi Arabia, Senegal, and Tunisia) reported their first confirmed new case. The daily incidence of COVID-19 outside of China has been higher than that in China since February 26, 2020 (459 versus 412). Thus, we should continue our undivided attention on the surveill-

Keywords: COVID-19; Viral infection; Epidemic; Coronavirus; Epidemiology.


Received: February 26, 2020; Revised: March 04, 2020; Accepted: March 05, 2020

Correspondence to: Lanjing Zhang, Department of Pathology, Princeton Medical Center, Plainsboro, NJ, USA. Tel: +1-609-853-6833; Fax: +1-609-853-6841; E-mail: lanjing.zhang@rutgers.edu


Exploratory Research and Hypothesis in Medicine 2020 vol. 5 | 6–7

Copyright: © 2020 Authors. This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
ing new drugs. The due diligence must not be jeopardized despite the urgent needs for these drugs because an approval of such drug will have long-lasting and profound effects in the world.

5. The care for non-infectious diseases may be deprived of needed resources. Largely due to lack of manpower and resources, one should anticipate and prepare for a significant rise in the deaths due to cardiovascular, pulmonary and other chronic diseases.

6. Psychologic issues of the general public, patients, patient-families, local officials and healthcare providers. A recent comment rightfully raise such a concern. If not timely and properly addressed, such a psychological issue will exhaust healthcare manpower, decrease morale and cause long-term psychological diseases among impacted individuals including patients, families and health care providers.

7. Documentation of related policies, implemented approaches and observed outcomes. This practice will be critical for tracking records, learning the lessons, enforce accountability and improving efficiency.

8. Information overload and errors in reporting. It is inevitable that the conventional media and social media will pour unprecedent amount of information to the public, who are eager to better understand the disease and current situation. The important and accountable information, however, might be buried in the information overload. Related parties should proactively reach out to the public to “advertise” credible information through new media. Errors in reporting or rumors are very difficult to identify and handle since they could be proven wrong only upon rigorous, long and time-consuming validation studies.

Another question of significant consequences is how to properly deal with the aftermath of the COVID-19 outbreak. Hopefully, the end of the COVID-19 outbreak will soon come. Many issues will emerge. Thus, experts in public health, socioeconomical, geopolitical and biomedical studies should work together to proactively articulate the related issues, discuss possible solutions and formulate feasible, yet impactful, action plans.

In summary, the eight blind spots may interest related parties. If these issues remain outstanding, they will likely lead to many severe harms to the public, healthcare providers and the economy. Additional research is therefore needed to better understand and address these blind spots in fighting the outbreak of coronavirus disease 2019.

Acknowledgments

The opinions expressed here are solely those of the author, and not of his affiliations.

Funding

None.

Conflict of interest

The author has no conflict of interest related to this publication.

References